Transplacental Flecainide and/or Digoxin for Fetal Tachyarrhythmias: Therapeutic Efficacy and Clinical Experience
Prenatal Diagnosis · 2026
DOI: 10.1002/pd.70278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2026. Verfasst von Mukpradab Darakamas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Tha…. Hauptthemen laut MEDLINE: Flecainide, Digoxin, Anti-Arrhythmia Agents, Fetal Diseases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To assess the efficacy and safety of transplacental flecainide and/or digoxin for fetal tachyarrhythmias when sotalol is unavailable.
Method
We evaluated transplacental flecainide, digoxin, or combination therapy in a retrospective and prospective cohort across two Thai tertiary centers. Outcomes were classified as complete cardioversion, partial response (rate control), or treatment failure.
Results
Of 24 eligible pregnancies, 14 (58.3%) had supraventricular tachycardia (SVT), 8 (33.3%) had atrial flutter (AFL), and 2 (8.3%) had ventricular tachycardia (VT). Overall, clinical responses occurred in 91.7% (22/24) of fetuses. Flecainide monotherapy achieved 100% (9/9) complete cardioversion in SVT, compared with 50% (1/2) for digoxin. SVT combination therapy ( n = 3) yielded 1 complete and 1 partial response. Among 7 flecainide‐treated AFL cases, 5 (71.4%) achieved rate control and 2 (28.6%) achieved cardioversion; one digoxin‐treated case fully converted. Flecainide resolved 1 of 2 VT cases (50%). Response rates were unaffected by hydrops, gestational age, or cardiac defects ( p = 0.087–1.000). Maternal adverse events were mild and required no treatment discontinuation.
Conclusion
Transplacental flecainide demonstrates high efficacy in SVT and effective rate control with preserved cardiac function in AFL. Its favorable safety profile makes it a practical alternative for first‐line therapy where sotalol is unavailable and flecainide monitoring is infeasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Fetal Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Mukpradab Darakamas, Sanitra Anuwutnavin, Fuanglada Tongprasert, Wisit Chankhunaphas
Zitieren
APA
Darakamas, M., Anuwutnavin, S., Tongprasert, F., Chankhunaphas, W., Nilto, K., Kanjanauthai, S., & Soongswang, J. (2026). Transplacental Flecainide and/or Digoxin for Fetal Tachyarrhythmias: Therapeutic Efficacy and Clinical Experience. Prenatal Diagnosis. https://doi.org/10.1002/pd.70278
Vancouver
Darakamas M, Anuwutnavin S, Tongprasert F, Chankhunaphas W, Nilto K, Kanjanauthai S, et al. Transplacental Flecainide and/or Digoxin for Fetal Tachyarrhythmias: Therapeutic Efficacy and Clinical Experience. Prenatal Diagnosis. 2026. doi:10.1002/pd.70278
BibTeX
@article{Darakamas2026,
author = {Darakamas, Mukpradab and Anuwutnavin, Sanitra and Tongprasert, Fuanglada and Chankhunaphas, Wisit and Nilto, Kanyarat and Kanjanauthai, Supaluck and Soongswang, Jarupim},
title = {Transplacental Flecainide and/or Digoxin for Fetal Tachyarrhythmias: Therapeutic Efficacy and Clinical Experience},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70278}
}
EUVIMED